Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
Rhythm Pharmaceuticals (Nasdaq: RYTM) filed an 8-K disclosing the June 24 2025 Annual Meeting results and a governance change.
- Officer exculpation amendment: Stockholders approved a charter change (55.5 M FOR / 3.5 M AGAINST) extending Delaware-permitted liability protection to certain officers; became effective upon June 25 2025 filing.
- Director elections: Jennifer Good re-elected with 55.6 M votes; Edward T. Mathers retained his seat with 35.2 M votes.
- Auditor confirmation: Ernst & Young LLP ratified for FY-2025 with 60.6 M (99.7 %) FOR.
- Say-on-pay: Executive compensation passed (40.9 M FOR, 18.1 M AGAINST).
- Quorum: 60.7 M votes present, representing 92.7 % of eligible votes.
No operational or financial metrics were updated; the lone material item is the officer liability shield, which may dilute shareholder recourse.
Rhythm Pharmaceuticals director Jennifer L. Good received new equity compensation grants on June 24, 2025, consisting of:
- 7,037 stock options with an exercise price of $63.66 per share, expiring June 23, 2035
- 4,712 restricted stock units (RSUs), each convertible into one share of common stock
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options and RSUs were granted at $0 cost to the director. This appears to be part of the company's regular annual director compensation program. The filing was submitted by Stephen Vander Stoep as attorney-in-fact for Jennifer Good.
Rhythm Pharmaceuticals (RYTM) director Edward T. Mathers received new equity compensation grants on June 24, 2025. The awards consist of:
- Stock Options: 7,037 options with an exercise price of $63.66, exercisable until June 23, 2035
- Restricted Stock Units (RSUs): 4,712 units, each convertible to one common share
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options provide the right to purchase shares at the specified strike price, while the RSUs represent a contingent right to receive shares upon vesting with no purchase requirement. This compensation structure aligns the director's interests with long-term shareholder value.
Rhythm Pharmaceuticals (RYTM) – Form 4 insider filing
Director Christophe Jean reported two equity awards dated 24 Jun 2025:
- Stock option: 7,037 shares of common stock, exercise price $63.66, expiration 23 Jun 2035. The option vests in full on the earlier of 24 Jun 2026 or the day before the company’s 2026 annual shareholder meeting, subject to continued board service.
- Restricted stock units (RSUs): 4,712 units, each convertible into one common share. Vesting schedule mirrors the option grant; the RSUs have no expiration date.
Both grants are coded "A" (acquired) and were made directly to the reporting person. Following the transactions, Jean beneficially owns 7,037 stock options and 4,712 RSUs; no common shares were reported in Table I and no sales occurred.
The filing represents routine non-cash director compensation and does not disclose any open-market purchase or sale of Rhythm Pharmaceuticals stock.
Form 4 overview: Rhythm Pharmaceuticals (RYTM) disclosed that director Stuart A. Arbuckle received new equity awards on 24 June 2025.
The filing records the grant of 7,037 stock options with a $63.66 exercise price, expiring 23 June 2035, and 4,712 restricted stock units (RSUs). Both awards fully vest on the earlier of 24 June 2026 or the day immediately before the 2026 annual stockholder meeting, provided the director remains on the board. No non-derivative common-stock transactions were reported, and the director now beneficially owns the full amount of these derivative securities.
This appears to be routine annual board compensation that aligns the director’s incentives with shareholders and carries minimal dilution, offering little direct impact on Rhythm’s near-term financial outlook.
Form 4 snapshot: On 06/24/2025, Rhythm Pharmaceuticals (ticker RYTM) filed a Form 4 reporting new equity awards to director Lynn A. Tetrault.
- Stock options: 7,037 options with a $63.66 exercise price, expiring 06/23/2035. Vest in full on the earlier of 06/24/2026 or the day before the 2026 annual meeting, subject to continued board service.
- Restricted stock units (RSUs): 4,712 units; each RSU converts into one common share. Vesting schedule matches the option grant; no expiration date.
- Post-grant holdings: 7,037 derivative securities (options) and 4,712 RSUs are now reported as beneficially owned. No common shares were bought or sold, and no dispositions occurred.
The filing reflects routine director compensation designed to align incentives; it does not disclose any share sales, purchases with cash, or changes to non-derivative ownership.